Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.32 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634192 | 0.83 | NTRK1 (0.42) | NTRK1NTRK2RIPK2GRM4PTGS2 | |
| SCHEMBL14633488 | 0.83 | GRM4 (0.49) | NTRK1NTRK2RIPK2GRM4MAP2K4 | |
| SCHEMBL2468759 | 0.82 | NTRK1 (0.44) | NTRK1NTRK2RIPK2LCKSYK | |
| SCHEMBL14634207 | 0.81 | RIPK2 (0.46) | RIPK2GAKLCKTGFBR1KCNH2 | |
| SCHEMBL14634292 | 0.81 | RIPK2 (0.44) | NTRK1NTRK2RIPK2PTGS2MAP2K4 | |
| SCHEMBL14633921 | 0.81 | SYK (0.35) | SYKPTGS2ITK | |
| SCHEMBL14633733 | 0.80 | PTGS2 (0.49) | NTRK1NTRK2RIPK2PTGS2MAP2K4 | |
| SCHEMBL2471505 | 0.80 | RIPK2 (0.42) | NTRK1NTRK2RIPK2SYKPTGS2 | |
| SCHEMBL2467824 | 0.78 | CDK9 (0.42) | NTRK1NTRK2RIPK2LCKPTGS2 | |
| SCHEMBL14634034 | 0.78 | EPHB4 (0.49) | NTRK2RIPK2LCKSYKPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | NTRK1 797/4885NTRK2 1690/4885RIPK2 443/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | NTRK1 628/4885NTRK2 1340/4885RIPK2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.